Analyst Group initiates coverage of Lumito
Lumito AB (publ) (”Lumito” or the “Company”) today announces that Analyst Group has initiated equity research coverage of Lumito, commissioned by the Company. The coverage includes equity research with quarterly updates as well as analyst comments on financial reports and press releases. Analyst Group’s full equity research report on the Company is expected to be […]
Lumito receives order from Swedish research unit
Lumito AB (publ) (“Lumito” or the “Company”) today announces that the Company has received an order for a SCIZYS Erbium kit from a research unit in Sweden. The customer will utilise the Company’s Scan-as-a-Service offering. The Company has received an order at an initial value of 10-20 kSEK from an organisation that has experienced limitations […]
Lumito publishes investor letter – 2025 in review and the road ahead
Lumito AB (publ) (“Lumito” or “the Company”) today announces the publication of its latest investor letter, which summarises the development in 2025 and also presents the Company’s priorities for 2026. “During 2025, we took several important steps in market introduction and commercialisation. We have methodically built insights, relationships, structures and processes, all of which are […]
Lumito’s technology enables quantification of low abundant cells
Lumito AB (publ) (“Lumito” or the “Company”) today announces new results from its collaboration with Truly Labs AB (“Truly Labs”), demonstrating that Lumito’s tissue analysis technology enables significantly improved detection of low abundant, “rare”, cells compared to conventional staining methods. The results were presented at the Pharma Outsourcing conference, organised by Life Science Sweden, on […]
Lumito AB publishes interim report for the third quarter of 2025
Financial overviewThird quarter 2025, 1 July – 30 September• Net sales amounted to 0 (0) KSEK, capitalised development contributed with 0 (418) KSEK• The net loss amounted to -9 511 (-10 844) KSEK.• Basic and diluted earnings per share amounted to -0.04 (-0.05) SEK.• Cash flow during the third quarter amounted to -3 084 (-6 156) […]
Invitation to webinar in connection with Lumito AB’s Q3 2025 Interim Report
Lumito AB (publ) (“Lumito” or the “Company”) will publish its report for the third quarter of 2025 on 27 November 2025. In connection with the publication, shareholders, investors, and other stakeholders are invited to a webinar on the same day at 14:00 CET. During the session, the Company’s CEO, Sanna Wallenborg, will provide a brief introduction […]
Lumito granted SEK 250,000 business development grant from Region Skåne
Lumito AB (publ) (“Lumito” or “the Company”) announces today that the Company has received a business development grant of SEK 250,000 from Region Skåne. Together with the proceeds from the recently completed rights issue, the funding will primarily be used to accelerate the Company’s commercial development and further strengthen its position in the European market. […]
Conversion of paid subscribed units (BTUs) and first day of trading in warrants of series TO7
THE INFORMATION IN THIS PRESS RELEASE MAY NOT BE ANNOUNCED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, INTO AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED KINGDOM, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE THE RELEASE, PUBLICATION OR DISTRIBUTION OF THE INFORMATION WOULD BE CONTRARY TO OR REQUIRE […]
Truly Labs AB include Lumito’s tissue analysis technology into its customer offering
Lumito AB (publ) (“Lumito” or the “Company”) today announces that Truly Labs AB (“Truly Labs”), following an evaluation period, has decided to include SCIZYS, Lumito’s product for advanced tissue analysis, in its service offering to research and pharmaceutical clients. The decision follows the pilot study jointly conducted by Lumito and Truly Labs earlier this year. […]
Last day of trading with unit rights in Lumito’s rights issue
THE INFORMATION IN THIS PRESS RELEASE MAY NOT BE ANNOUNCED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, INTO AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED KINGDOM, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE THE RELEASE, PUBLICATION OR DISTRIBUTION OF THE INFORMATION WOULD BE CONTRARY TO OR REQUIRE […]